YellowLegalPad Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : YellowLegalPad

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: John McCarthy who wrote (1144)	9/21/2010 3:46:18 AM
From: John McCarthy	Read Replies (1) of 1182

CHTP (6) Some thoughts on todays conference call. They were a happy bunch. Have obviously given a lot of thought to the marketing. Still being very conservative, which I like. Pointed out the composite scoring will allow them to place other things on the label besides dizziness. Not all potential patients will suffer from dizziness, so its a big plus to be able to say it can relieve additional symptoms and this increases the market potential of Northera. Still planning on 30 dollars a day cost for the drug. Once again there were no falls in the treatment group and 3 falls in the placebo group. Lots of excitement about this and they even called decreasing falls "the holy grail." Mentioned projections that by the year 2050 the annual cost of treating injuries from falls will be 50 billion dollars and that 30% of Parkinsons patients that are hospitalized, are hospitalized because of falls. Pointed out that with what they know now (these trials are first of a kind), the longer term design of 306 should show even more pronounced effects for the Parkinsons patients, a group that seems to require a longer treatment than the autonomic group to see maximal efficacy. messages.finance.yahoo.com CRACKER

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next